K. Bragman

707 total citations
16 papers, 545 citations indexed

About

K. Bragman is a scholar working on Molecular Biology, Infectious Diseases and Virology. According to data from OpenAlex, K. Bragman has authored 16 papers receiving a total of 545 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Infectious Diseases and 5 papers in Virology. Recurrent topics in K. Bragman's work include HIV Research and Treatment (5 papers), HIV/AIDS drug development and treatment (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). K. Bragman is often cited by papers focused on HIV Research and Treatment (5 papers), HIV/AIDS drug development and treatment (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). K. Bragman collaborates with scholars based in United States, United Kingdom and Italy. K. Bragman's co-authors include Renzo Canetta, Laurie Smaldone, Marcel Rozencweig, Demetrios Papahadjopoulos, Timothy D. Heath, Jonathan Weber, I. B. R. Duncan, Charlotte Skinner, V. S. Kitchen and A J Pinching and has published in prestigious journals such as The Lancet, JNCI Journal of the National Cancer Institute and Annals of the New York Academy of Sciences.

In The Last Decade

K. Bragman

16 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K. Bragman United States	12	205	177	131	126	82	16	545
Laurie Smaldone United States	10	335 1.6×	265 1.5×	161 1.2×	86 0.7×	72 0.9×	18	685
Pamela Boyer United States	14	494 2.4×	284 1.6×	134 1.0×	144 1.1×	28 0.3×	24	959
Philippe Hermans Belgium	14	389 1.9×	266 1.5×	367 2.8×	101 0.8×	157 1.9×	37	913
David Dolling United Kingdom	13	165 0.8×	111 0.6×	167 1.3×	113 0.9×	15 0.2×	27	579
Wendy Bannister United Kingdom	15	329 1.6×	204 1.2×	332 2.5×	217 1.7×	13 0.2×	29	938
Evan L. Busch United States	12	80 0.4×	25 0.1×	132 1.0×	133 1.1×	33 0.4×	18	515
Hugo Troonen Germany	10	108 0.5×	28 0.2×	37 0.3×	75 0.6×	12 0.1×	19	457
J.A. Gastaut France	16	251 1.2×	122 0.7×	287 2.2×	149 1.2×	145 1.8×	38	1.1k
A. Molinari Italy	10	109 0.5×	29 0.2×	187 1.4×	44 0.3×	18 0.2×	17	568
Johannes Mejer Denmark	10	46 0.2×	29 0.2×	179 1.4×	122 1.0×	66 0.8×	29	397

Countries citing papers authored by K. Bragman

Since Specialization

Citations

This map shows the geographic impact of K. Bragman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Bragman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Bragman more than expected).

Fields of papers citing papers by K. Bragman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Bragman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Bragman. The network helps show where K. Bragman may publish in the future.

Co-authorship network of co-authors of K. Bragman

This figure shows the co-authorship network connecting the top 25 collaborators of K. Bragman. A scholar is included among the top collaborators of K. Bragman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Bragman. K. Bragman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Brock, Peter, et al.. (2006). Ethics and pharmaceutical medicine - the full report of the Ethical Issues Committee of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK. International Journal of Clinical Practice. 60(2). 242–252. 9 indexed citations

Brock, Peter, et al.. (2006). Guiding Principles for Pharmaceutical Physicians from the Ethical Issues Committee of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK. International Journal of Clinical Practice. 60(2). 238–241. 5 indexed citations

Hawkins, David, Nathan Clumeck, David A. Cooper, et al.. (2000). Randomised, Multicentre Phase III Study of Saquinavir plus Zidovudine plus Zalcitabine in Previously Untreated or Minimally Pretreated HIV-Infected Patients. Clinical Drug Investigation. 20(5). 295–307. 13 indexed citations

Jacobsen, Helmut, S. Galpin, Lucy Dorrell, et al.. (1997). Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. Journal of Antimicrobial Chemotherapy. 39(6). 771–779. 27 indexed citations

Bragman, K.. (1996). Saquinavir: An HIV Proteinase Inhibitor. Advances in experimental medicine and biology. 305–317. 25 indexed citations

Vella, Stefano, Adriano Lazzarin, Giampiero Carosi, et al.. (1996). A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.. PubMed. 1(3). 129–40. 15 indexed citations

Kitchen, V. S., Charlotte Skinner, Koya Ariyoshi, et al.. (1995). Safety and activity of saquinavir in HIV infection. The Lancet. 345(8955). 952–955. 148 indexed citations

Mangioni, C., Giorgio Bolis, S. Pecorelli, et al.. (1989). Randomized Trial in Advanced Ovarian Cancer Comparing Cisplatin and Carboplatin. JNCI Journal of the National Cancer Institute. 81(19). 1464–1471. 110 indexed citations

Canetta, Renzo, K. Bragman, Laurie Smaldone, & Marcel Rozencweig. (1988). Carboplatin: current status and future prospects. Cancer Treatment Reviews. 15. 17–32. 91 indexed citations

10.

Canetta, Renzo, C.R. Franks, Laurie Smaldone, K. Bragman, & Marcel Rozencweig. (1987). Clinical status of carboplatin.. PubMed. 1(5). 61–70. 18 indexed citations

11.

Dhaliwal, Harpal S., Michael J. Barnett, H. G. Prentice, et al.. (1986). Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside. Cancer Chemotherapy and Pharmacology. 18(1). 59–62. 12 indexed citations

12.

Papahadjopoulos, Demetrios, Timothy D. Heath, K. Bragman, & Katherine K. Matthay. (1985). New Methodology for Liposome Targeting to Specific Cells^a. Annals of the New York Academy of Sciences. 446(1). 341–348. 14 indexed citations

13.

Barnett, M. J., M A Richards, TS Ganesan, et al.. (1985). High-dose cytosine arabinoside in the initial treatment of acute leukemia.. PubMed. 12(2 Suppl 3). 133–8. 8 indexed citations

14.

Bragman, K., Timothy D. Heath, & Demetrios Papahadjopoulos. (1984). Cytotoxicity of Antibody-Directed Liposomes That Recognize Two Receptors on K562 Cells<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref>. JNCI Journal of the National Cancer Institute. 73(1). 127–31. 14 indexed citations

15.

Heath, Timothy D., et al.. (1984). Antibody-directed liposomes: the development of a cell-specific cytotoxic agent. Biochemical Society Transactions. 12(2). 340–342. 6 indexed citations

16.

Bragman, K., Timothy D. Heath, & Demetrios Papahadjopoulos. (1983). Simultaneous interaction of monoclonal antibody-targeted liposomes with two receptors on K562 cells. Biochimica et Biophysica Acta (BBA) - Biomembranes. 730(2). 187–195. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact